A Monoclonal Antibody Quantitative Measurement And Immunohistochemical Localisation Of Carcinoembryonic Antigen In Ovarian Neoplasia

Abstract

Objective: To evaluate the significance of including CEA in serum and tissues in the management protocol of patients with ovarian malignancies. Patients And Methods: The study included 68 patients which was divided into three groups. Group [A] included 21 patients with malignant ovarian tumors. Group included three patients with boderline ovarian tumors. Group [C] included eight patients with benign ovarian tumors, Group [D] included 36 women without any apparent gynaecologic disorder ( control group). Serum level of CEA was measured in all patients in group A, B and C prior to treatment and at least 12 weeks following therapy. Formalin fixed and paraffin embedded tissue blocks taken from 2 different sites of the studied lesions were prepared. Immunohistochemical staining for CEA was performed for the studied tissues. Results: All the ovarian tumors investigated in this work were of epithelial origin. All benign and borderline ovarian tumors had negative preand post-treatment serum CEA levels ( =5ng/ml) pre-treatment serum levels. After treatment the different histological types of ovarian carcinimas were seronegative for CEA.The highest percentage of positive staining (100%) was found in squamous cell carcinomas [50% (+1) and 50% (+3)], followed by 66.67% of mucinous cystadenocarcinomasThe mean difference between pre-and posttreatment serum CEA was significant in mucinous cystadinocarcinoma with negative and positive tissue reaction and in negatively stained serous cystadinomacarcinoma.The percentages of cases of ovarian carcinomas with positive pretreatment serum CEA increased with the increase of grade of malignancy from 33.33% in G1 to 55.56% in G II and 66.67% in GIII.No definite relation could be detected between the grade of malignancy and the intensity (degree) of reaction of malignant ovarian tumors to CEA immunostaining.The percentage of cases with positive pre-treatment levels of serum CEA increased progressively with the advance in clinical staging. The incidence was 37.5% in stage I, 55.56% in stage II, 66.67% in stage III, and 100% in stage IV. No definite relation could be detected between the clinical stages and the degree of reaction of ovarian carcinomas to CEA tissue stain. Conclusion: This study indicated that immunohistochemical identification of CEA in tumor tissue and of monoclonal antibodies quantitative measurement of CEA in human serum is a useful adjunct in the management protocol of patients with ovarian malignancies. However further studies are required to fully ascertain the usefullness of this technique. A Monoclonal Antibody Quantitative Measurement And Immunohistochemical Localisation Of Carcinoembryonic Antigen In Ovarian Neoplasia 2 of 1